A Study of BGB-11417 in Participants With Myeloid Malignancies
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and
preliminary efficacy of BGB-11417 in combination with azacitidine in participants with acute
myeloid leukemia (AML) and myelodysplastic syndrome (MDS).